Improvement of accommodation with anti-oxidant supplementation in visual display terminal users

Journal of Nutrition, Health and Aging

Volumn 16, Issue 5, 2012, Pages 478-481

  Uchino, Y ^a   Uchino, M ^a   Dogru, M ^a   Fukagawa, K ^a   Tsubota, K ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Accommodation; Antioxidant supplements; Nutrition; Visual Display Terminal (VDT)

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ASTAXANTHIN; BETA CAROTENE; BLUEBERRY EXTRACT; COPPER; NICOTINIC ACID; PLACEBO; XANTHOPHYLL; ZINC;

ACCOMMODATION; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISPLAY SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EYE REFRACTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL DISPLAY TERMINAL; VISUAL DISPLAY UNIT;

EID: 85027920442     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0059-3     Document Type: Article

References (33)

1. Von Helmholtz H (1885) Uber die akkommodation des auges. Archiv Ophthalmol 1, 1-74.
2. Duane A (1912) Normal values of the accommodation at all ages. JAMA 59, 1010.
3. Koretz J F, Kaufman P L, neider M w et al. (1989) accommodation and presbyopia in the human eye: aging of the anterior segment. Vision res 29, 1685.
4. Nishida S, Mizutani S. (1992) Quantitative and morphometric studies of age-related changes in human ciliary muscle. Jpn J ophthalmol 36, 380-7. (Pubitemid 23035191)
5. Pardue MT, Sivak JG. (2000) Age-related changes in human ciliary muscle. Optom Vis sci 77, 204-10. (Pubitemid 30241521)
6. Glasser A, Cambell MCW (1999) Biometric, optical and physical changes in the isolated humancrystalline lens with age in relation to presbyopia. Vision res 39, 1991-2015. (Pubitemid 29156718)
7. Nagaki Y, Mihara M, Tsukahara h et al. (2006) The supplementation effect of astaxanthin on accommodation and asthenopia. rinsho Iyaku 22, 41-54.
8. Koide R, Ueda T (1994) Effects of whortleberry extract on ocular function. Journal of the Eye 11, 117-121.
9. Miki W (1989) Biological function and activities of animal carotenoids. Pure & Appl. Chem. 63, 141-146.
10. Shimizu N, Goto M, Miki W (1996) carotenoids as singlet oxygen quenchers in marine organism. Fish sci 62, 134-137. (Pubitemid 126417807)
11. Chow SC, Liu JP (2004) sample size determination. in: Design and analysis of clinical Trials. concept and Methodologies. Eds: balding DJ, noel ac., new Jersey, U.S.A., wiley interscience inc; 438-510.
12. Valero MP, Fletcher AE, DE stavola BL et al. (2002) Vitamin Cis associated with reduced risk of cataract in a Mediterranean population. J Nutr 132, 1299-306. (Pubitemid 34606468)
13. Taylor A, Jacques PF, Chylack LT Jr et AL. (2002) Long-term intake of vitamins and carotenoids and odds of early age-related cortical and posterior subcapsular lens opacities. am J clin nutr 75, 540-9. (Pubitemid 34174949)
14. Leske MC, Chylack LT JR, WU SY (1991) The Lens opacities case-control study. risk factors for cataract. Arch Ophthalmol 109, 244-51.
15. Yoshida M, Takashima Y, Inoue M et al. (2007) JPhc study group. Prospective study showing that dietary vitamin c reduced the risk of age-related cataracts in a middle-aged Japanese population. Eur J nutr 46, 118-24. (Pubitemid 46295317)
16. Age-Related Eye Disease Study research Group. (2001) A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins c and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no.8. Arch Ophthalmol 119, 1417-36.
17. Iwasaki T, Kurimoto s (1987) Effect of methylcobalamin in accommodative dysfunction of eye by visual load. J UoEh 9, 127-32.
18. Bruckner G (1997) Microcirculation, Vitamin E and omega 3 fatty acids: an overview. Adv Exp Med biol 415, 195-208. (Pubitemid 27187673)
19. Lehr HA, Vajkoczy P, Menger MD (1998) Vitamin E: focus on microcirculation. Microcirculation 5, 117-28. (Pubitemid 128647888)
20. Pashkow FJ, Watumull DG, Campbell cL (2008) astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. am J cardiol 22, 101 (10a): 58D-68D.
21. Suzuki Y, Ohgami K, Shiratori K et al. (2006) suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the nF-kappab signaling pathway. Exp Eye res 82, 275-81. (Pubitemid 43122113)
22. Ohgami K, Shiratori K, Kotake S et al. (2003) Effects of astaxanthin on lipopolysaccharide -induced inflammation in vitro and in vivo. invest ophthalmol Vis Sci 44, 2694-701. (Pubitemid 36618432)
23. Kamath BS, srikanta BM, Dharmesh sM et al. (2008) Ulcer preventive and antioxidative properties of astaxanthin from haematococcus pluvialis. Eur J Pharmacol 590, 387-95.
24. Manabe E, Handa O, Naito Y et al. (2008) Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell biochem 103, 1925-37. (Pubitemid 351501922)
25. Naito Y, Uchiyama K, Mizushima K et al. (2006) Microarray profiling of gene expression patterns in glomerular cells of astaxanthin-treated diabetic mice: a nutrigenomic approach. Int J Mol Med 18, 685-95.
26. Naito Y, Uchiyama K, Aoi W et al. (2004) Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. biofactors 20, 49-59. (Pubitemid 38586209)
27. Uchiyama K, Naito Y, Hasegawa G et al. (2002) astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox rep 7, 290-3. (Pubitemid 36032916)
28. Aoi W, Naito Y, Sakuma K et al. (2003) astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. antioxid redox signal 5, 139-44. (Pubitemid 36337025)
29. Kurashige M, okimasu E, inoue M et al. inhibition of oxidative injury of biological membranes by astaxanthin. Physiol. chem. Phys. & Med nMr 1990; 22: 27-38.
30. Goto S, Kogure K, Abe K et al. (2001) Efficient radical trapping at the surface and inside the phospholipids membrane is responsible for highly potent antiperosidatibe activity of the carotenoid astazanthin. biochem. biophys. Asta. 1512, 241-258.
31. Hussein G, Nakamura M, Zhao Q et al. (2005) anti-hypertensive and neuroprotective effects of astaxanthin in experimental animals. biol Pharm bull 28, 47-52. (Pubitemid 40879782)
32. Mcginty SJ, Truscott RJ. (2006) Presbyopia: the first stage of nuclear cataract? Ophthalmic Res 38, 137-48. (Pubitemid 43780873)
33. Truscott RJ. (2005) Age-related nuclear cataract-oxidation is the key. Exp Eye Res 80, 709-25.